Urothelial carcinoma of the bladder with transmural and direct prostatic stromal invasion: does extent of stromal invasion significantly impact patient outcome?

Oliva, Irma; Smith, Sarah M.; Osunkoya, Adeboye O.

doi:10.1016/j.humpath.2010.06.013

Cited by 14 publications

(11 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oliva et al found no difference in median OS when comparing focal vs extensive extramural prostatic invasion in 35 patients (17.4 vs 16.3 months). 21 These findings support the theory that tumor biology of transmural/extramural prostatic invasion, whether focal or extensive, may be more aggressive than SSI.…”

Section: Discussionsupporting

confidence: 79%

Validation of New AJCC Exclusion Criteria for Subepithelial Prostatic Stromal Invasion from pT4a Bladder Urothelial Carcinoma

et al. 2013

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 79%

Validation of New AJCC Exclusion Criteria for Subepithelial Prostatic Stromal Invasion from pT4a Bladder Urothelial Carcinoma

et al. 2013

View full text Add to dashboard Cite

show abstract

“…• On multivariable analysis, higher prostate tumour stage (hazard ratio [HR] 2.09; P = 0.01), positive lymph node status (HR 2.09; P = 0.002), and concurrent ≥pT3 bladder cancer (HR 4. 16; P < 0.001) were significantly associated with an increased risk of death from UC.…”

Section: Resultsmentioning

confidence: 93%

“…Prostatic involvement of urothelial carcinoma (UC) has been reported in 15-48% of RC specimens, with known risk factors for prostatic involvement including bladder tumour multifocality, presence of carcinoma in situ (CIS/pTis), and presence of a bladder neck or trigonal tumour [2][3][4][5][6][7][8][9][10][11]. Notably, however, conflicting data have been reported about the prognostic importance of prostatic involvement by bladder cancer [12][13][14][15][16][17]. Moreover, in 2010, the American Joint Committee on Cancer (AJCC) revised the classification of prostatic UC according to the depth and mode of invasion [18].…”

Section: Introductionmentioning

confidence: 99%

Urothelial carcinoma involving the prostate: the association of revised tumour stage and coexistent bladder cancer with survival after radical cystectomy

et al. 2014

View full text Add to dashboard Cite

Objective• To evaluate survival among patients with urothelial carcinoma (UC) within the prostate in order to assess the impact of depth of tumour invasion as well as the importance of a concurrent bladder tumour. Patients and Methods• We identified 201 patients who underwent radical cystectomy (RC) between 1980 and 2006 and were found to have UC involving the prostate.• All specimens were re-reviewed by a genitourinary pathologist.• Survival was estimated using the Kaplan-Meier method and compared with the log-rank test. Cox hazard regression models tested the association of clinicopathological variables with outcome. Results• In all, 93 patients had pTis disease in the prostate, 43 had pT2 tumours, and 66 patients were pT4a. The median follow-up was 10.5 years.• The 5-year cancer-specific survival for patients with pTis, pT2, and pT4a prostate UC was 73%, 57%, and 21% respectively (P < 0.001).• On multivariable analysis, higher prostate tumour stage (hazard ratio [HR] 2.09; P = 0.01), positive lymph node status (HR 2.09; P = 0.002), and concurrent ≥pT3 bladder cancer (HR 4.16; P < 0.001) were significantly associated with an increased risk of death from UC. Conclusions• Among patients with prostatic UC involvement, depth of tumour invasion was significantly associated with cancer-specific mortality, validating the staging reclassification.• Concurrent locally advanced bladder cancer also negatively impacted survival, suggesting the potential prognostic value of reporting a secondary tumour stage in such cases.

show abstract

“…This case, originally signed out as in situ UC involving prostatic ducts, was revised as having PSI. nosis, but even a few cases with focal PSI may have similarly poor prognosis [16,17]. Therefore, it is essential to find even focal areas of PSI for proper classification.…”

Section: Resultsmentioning

confidence: 99%

Double cocktail immunostains with high molecular weight cytokeratin and GATA-3: useful stain to discriminate in situ involvement of prostatic ducts or acini from stromal invasion by urothelial carcinoma in the prostate

Lee

Yoo

Park

et al. 2020

J Pathol Transl Med

View full text Add to dashboard Cite

Background: Distinguishing prostatic stromal invasion (PSI) by urothelial carcinoma (UC) from in situ UC involving prostatic ducts or acini with no stromal invasion (in situ involvement) may be challenging on hematoxylin and eosin stained sections. However, the distinction between them is important because cases with PSI show worse prognosis. This study was performed to assess the utility of double cocktail immunostains with high molecular weight cytokeratin (HMWCK) and GATA-3 to discriminate PSI by UC from in situ UC involvement of prostatic ducts or acini in the prostate. Methods: Among 117 radical cystoprostatectomy specimens for bladder UCs, 25 cases showed secondary involvement of bladder UC in prostatic ducts/acini only or associated stromal invasion and of these 25 cases, seven cases revealed equivocal PSI. In these seven cases with equivocal PSI, HMWCK, and GATA-3 double immunohistochemical stains were performed to identify whether this cocktail stain is useful to identify the stromal invasion. Results: In all cases, basal cells of prostate glands showed strong cytoplasmic staining for HMWCK and UC cells showed strong nuclear staining for GATA-3. In cases with stromal invasion of UC, GATA-3-positive tumor cells in the prostatic stroma without surrounding HMWCK-positive basal cells were highlighted and easily recognized. Among seven equivocal cases, two cases showed PSI and five in situ UC in the prostate. In two cases, the original diagnoses were revised. Conclusions: Our study suggested that HMWCK and GATA-3 double stains could be utilized as an adjunct method in the distinction between PSI by UC from in situ UC involving prostatic ducts or acini.

show abstract

Urothelial carcinoma of the bladder with transmural and direct prostatic stromal invasion: does extent of stromal invasion significantly impact patient outcome?

Cited by 14 publications

References 15 publications

Validation of New AJCC Exclusion Criteria for Subepithelial Prostatic Stromal Invasion from pT4a Bladder Urothelial Carcinoma

Validation of New AJCC Exclusion Criteria for Subepithelial Prostatic Stromal Invasion from pT4a Bladder Urothelial Carcinoma

Urothelial carcinoma involving the prostate: the association of revised tumour stage and coexistent bladder cancer with survival after radical cystectomy

Double cocktail immunostains with high molecular weight cytokeratin and GATA-3: useful stain to discriminate in situ involvement of prostatic ducts or acini from stromal invasion by urothelial carcinoma in the prostate

Contact Info

Product

Resources

About